The CYP2C19*2 and CYP2C19*17 Polymorphisms Influence Responses to Clozapine for the Treatment of Schizophrenia

INTRODUCTION: Clozapine (CLZ) is the gold standard drug for treatment-refractory schizophrenia (TRS). However, approximately 30% of patients partially respond to CLZ, defining this subset with super refractory schizophrenia (SRS). Alterations in enzyme activity may affect CLZ responses; the CYP3A4,...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodrigues-Silva, Christielly, Semedo, Agostinho Tavares, Neri, Hiasmin Franciely da Silva, Vianello, Rosana Pereira, Galaviz-Hernández, Carlos, Sosa-Macías, Martha, de Brito, Rodrigo Bernini, Ghedini, Paulo César
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023876/
https://www.ncbi.nlm.nih.gov/pubmed/32103962
http://dx.doi.org/10.2147/NDT.S228103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023876/
https://www.ncbi.nlm.nih.gov/pubmed/32103962
http://dx.doi.org/10.2147/NDT.S228103

Ejemplares similares